Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
- Status
- RECRUITING
- Phase
- PHASE4
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
D9319C00001- 1L OC Mono Global RCT
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Status
- TERMINATED
- Phase
- NA
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
- Status
- RECRUITING
- Phase
- PHASE2
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
- Status
- TERMINATED
- Phase
- PHASE3
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
- Status
- RECRUITING
- Phase
- PHASE2
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
- Status
- UNKNOWN
- Phase
- PHASE2